⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11041636 | 0.77 | F2R (0.32) | — | |
| SCHEMBL1578791 | 0.76 | KDM4E (0.50) | — | |
| SCHEMBL6706827 | 0.74 | KDM4E (0.42) | — | |
| SCHEMBL27573501 | 0.74 | KDM4E (0.48) | — | |
| SCHEMBL47351 | 0.74 | ALDH1A1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL19136144 | 0.74 | KDM4E (0.48) | — | |
| SCHEMBL6347415 | 0.72 | — | — | |
| SCHEMBL22769448 | 0.72 | — | — | |
| SCHEMBL21690925 | 0.72 | — | — | |
| SCHEMBL2827132 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608823-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024088922-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-02 | — | — | WO | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20100197749-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB | 2010-08-05 | — | — | US | disclosed |
| US-20100197749-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB | 2010-08-05 | — | — | US | disclosed |
| US-20100197749-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB | 2010-08-05 | — | — | US | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1979332-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007083089-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007083089-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |